Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Current Deferred Revenue for 3 consecutive years, with $8.2 million as the latest value for Q4 2023.

  • On a quarterly basis, Current Deferred Revenue fell 76.52% to $8.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $8.2 million, a 76.52% decrease, with the full-year FY2023 number at $8.2 million, down 76.52% from a year prior.
  • Current Deferred Revenue was $8.2 million for Q4 2023 at Actinium Pharmaceuticals, down from $35.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $35.0 million in Q3 2022 to a low of $100000.0 in Q1 2022.
  • A 3-year average of $16.6 million and a median of $8.2 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 34900.0% in 2023; the steepest drop was 76.52% in 2023.
  • Actinium Pharmaceuticals' Current Deferred Revenue stood at $1.0 million in 2021, then soared by 3400.0% to $35.0 million in 2022, then plummeted by 76.52% to $8.2 million in 2023.
  • Per Business Quant, the three most recent readings for ATNM's Current Deferred Revenue are $8.2 million (Q4 2023), $35.0 million (Q3 2023), and $100000.0 (Q2 2023).